MX2023003424A - Composiciones y metodos para inhibir la expresion genica. - Google Patents
Composiciones y metodos para inhibir la expresion genica.Info
- Publication number
- MX2023003424A MX2023003424A MX2023003424A MX2023003424A MX2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- gene expression
- inhibiting gene
- expression
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a represores de la expresión y a sistemas de represión de la expresión para modular la expresión de un gen diana en una célula.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063082555P | 2020-09-24 | 2020-09-24 | |
US202163242957P | 2021-09-10 | 2021-09-10 | |
PCT/US2021/051945 WO2022067033A1 (en) | 2020-09-24 | 2021-09-24 | Compositions and methods for inhibiting gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003424A true MX2023003424A (es) | 2023-05-03 |
Family
ID=80845810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023003424A MX2023003424A (es) | 2020-09-24 | 2021-09-24 | Composiciones y metodos para inhibir la expresion genica. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230399640A1 (es) |
EP (1) | EP4217477A1 (es) |
JP (1) | JP2023543218A (es) |
KR (1) | KR20230074525A (es) |
AU (1) | AU2021350024A1 (es) |
MX (1) | MX2023003424A (es) |
WO (1) | WO2022067033A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
GB2617474A (en) | 2020-11-04 | 2023-10-11 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of use thereof |
WO2023057880A1 (en) * | 2021-10-05 | 2023-04-13 | Glaxosmithkline Intellectual Property Development Limited | Crispr/cas9-based fusion proteins for modulating gene expression and methods of use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2800811T (pt) * | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
WO2017031370A1 (en) * | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
US9896696B2 (en) * | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
EP3867368A4 (en) * | 2018-10-15 | 2022-08-10 | Flagship Pioneering Innovations V, Inc. | DESTROYING THE ASSEMBLY OF A GENOMIC COMPLEX IN FUSION GENES |
EP3918059A4 (en) * | 2019-01-29 | 2022-11-30 | Flagship Pioneering Innovations V, Inc. | COMPOSITIONS CONTAINING AN ENDONUCLEASIS AND METHODS OF PURIFICATION OF AN ENDONUCLEASE |
-
2021
- 2021-09-24 AU AU2021350024A patent/AU2021350024A1/en active Pending
- 2021-09-24 US US18/246,480 patent/US20230399640A1/en active Pending
- 2021-09-24 MX MX2023003424A patent/MX2023003424A/es unknown
- 2021-09-24 EP EP21873514.0A patent/EP4217477A1/en active Pending
- 2021-09-24 JP JP2023518775A patent/JP2023543218A/ja active Pending
- 2021-09-24 KR KR1020237013601A patent/KR20230074525A/ko unknown
- 2021-09-24 WO PCT/US2021/051945 patent/WO2022067033A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR20230074525A (ko) | 2023-05-30 |
EP4217477A1 (en) | 2023-08-02 |
JP2023543218A (ja) | 2023-10-13 |
AU2021350024A1 (en) | 2023-05-04 |
US20230399640A1 (en) | 2023-12-14 |
AU2021350024A9 (en) | 2023-07-13 |
WO2022067033A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023003424A (es) | Composiciones y metodos para inhibir la expresion genica. | |
MX2022010991A (es) | Metodos y composiciones para modular un genoma. | |
EP4265261A3 (en) | Methods and compositions for inhibiting expression of ldha | |
MX2021012645A (es) | Metodos y composiciones para editar acidos ribonucleicos (arn). | |
AU2017261380A1 (en) | Genetically engineered cells and methods of making the same | |
MX2022001199A (es) | Compuestos de urea, amida y heteroarilo sustituido para la inhibicion de cbl-b. | |
WO2018129404A8 (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
MX2019011469A (es) | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). | |
MX2018004263A (es) | Edición genómica multiplexada. | |
PH12021550846A1 (en) | Compositions and methods for expressing factor ix | |
WO2018097540A3 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
GB2458863A (en) | Improved culture of stem cells | |
MX2019005476A (es) | Ensayo de celulas madre pluripotentes. | |
MX361278B (es) | Inhibición o reducción del crecimiento de hongos. | |
UY35088A (es) | Inhibidores de glutamina sintetasa de planta y métodos para su identificación | |
AU2018271755A1 (en) | Method for culturing natural killer cell, using transformed T cell | |
MX2018009247A (es) | Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. | |
MX2018012629A (es) | Diferenciacion de celulas madre pluripotentes a celulas de endodermo intestinal del intestino medio. | |
PH12020552291A1 (en) | System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host | |
EP3973048A4 (en) | COMPOSITIONS AND METHODS OF PLANT CELL GROWING | |
MX2019009514A (es) | Sustrato de lamina de acero inoxidable para separadores de celdas de combustible y metodo de produccion del mismo. | |
MX2020011470A (es) | Metodos de terapia genica. | |
WO2022132195A3 (en) | Compositions and methods for modulation myc expression | |
MX2022012829A (es) | Metodo para tratamiento de medio antes de inoculacion. | |
MX2021011609A (es) | Moduladores de interacciones de proteinas de superficie celular y metodos y composiciones relacionados con estos. |